



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, September 29, 2016 1:00-5:00 PM

Hewlett-Packard Building

Salem, OR 97302

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

Members Present: Bill Origer, MD; Tracy Klein, PhD, FNP; Rich Clark, MD, MPH; James Slater, PharmD; Walter Hardin, D.O., MBA; Caryn Mickelson, PharmD; Kelley Burnett, D.O; Cathy Zehrung, RPh; Stacy Ramirez, PharmD

Members Present by Phone:

Staff Present: Andrew Gibler, PharmD; Megan Herink PharmD, BCPS; Richard Holsapple, RPh; Roger Citron, RPh; Ted Williams, PharmD, BCPS; Dee Weston; Dave Engen, PharmD, CGP; Sarah Servid, PharmD; Kim Wentz, MD; Deanna Moretz, PharmD, BCPS; Lindsay Newton; Amber Vester;

Staff Present by Phone: Kathy Sentena, PharmD

Audience: Barrt Benson/Merck; *Brian Carlson/Ipsen; *May Kwong/Janssen; *Anthony Wheeler/Lilly; Venus Holder/Lilly; Teresa Blair/Ipsen; Todd Gavin/Indiveor; Rick Frees/Vemex; Jim Graves/BMS; *Anthony Hager/BMS; Lisa Boyle/WVP Health Authority; Stephanie Yamamoto/Janssen; *Cheri Lindberg/Indiveor; *Margaret Olmon/AbbVie; Cheryl Fletcher/AbbVie; *Raulo Frear/Merck; *Marc Jensen/Pfizer; *Stuart O'Brochta/Gilead; Becky Gonzales/Viiv Healthcare; *Andrea Scherschel/BMS; Emily Church/Salud Medical Center; Cassandra Miller/CareOregon; Tony Koehn/CareOregon; Martha Groeneveld/Synergy Pharma; Jennifer Snidler/SanofiGergne; Wisam Younis/Providence Health Plan; *Rose Mullen/Alkermes; Tim McFerron/Alkermes; *Mary Kemhus/Novartis; Wm Kennon/Primary Health; (Cannot make out name)/Pharmacy Student; Brian Heapde/Abbne; Luis Gonzalez/Salud Medical Center; Dean Haxby/OSU; Kerry Kostman Bonilla/AZ; Allison Naumoski/AZ; Hival Patel/AZ; Amy Burns/AllCare; Melissa Snider/Biomarin; Michael Estoos/Pfizer; *Sara Love/CCO Oregon; Kaysen Bala/Novo Nordisk; *Lorren Sandt; Kristel Jordan; *John McIlveen/OHA; *BJ Caunor/One in Four ChronicHealthy; Kerrie Fowler/Umpqua Health Alliance; *Kent Benner; Amy Bowman/Gilead; Tamatha Tracer/IHN CCO

(*) Provided verbal testimony

I. CALL TO ORDER

- A. The meeting was called to order at approximately 1:04 pm. Introductions were made by Committee members and staff.
- B. Mr. Citron reported there were no new conflicts of interest to declare.
- C. Approval of agenda and July minutes presented by Mr. Citron. (pages 4 - 9)

ACTION: Motion to approve, 2nd, All in Favor.

- D. Department updates for OHA presented by Dr. Jim Rickards.

II. DUR OLD BUSINESS

- A. Botulinum Toxins (page 10)
 - 1. Approve updated botulinum toxin PA criteria

ACTION: Motion to approve, 2nd. All in favor. Approved.

III. PREFERRED DRUG LIST NEW BUSINESS

- A. Newer Diabetes Agents Drug Class Update (pages 34 – 47)
Dr. Sentena presented the class update and following recommendations:
 - 1. No changes to the PMPDP based on the clinical evidence
 - 2. Continue current clinical PA criteria
 - 3. Approve GLP-1 receptor agonist PA modification
 - 4. Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd. All in favor. Approved.

- B. Asthma/COPD Drug Class Update (pages 48 - 82)
Dr. Sentena presented the scan and the following recommendations:
 - 1. No changes to the PMPDP based on the clinical evidence
 - 2. Continue current clinical PA criteria and add “without COPD” to Q#3 in LAMA/LABA criteria
 - 3. Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd. All in favor. Approved.

- C. Biologics Drug Class Update (pages 83 – 117)
Dr. Gibler presented the scan and following recommendations:

1. DERP Summary Review/Prior Authorization Criteria
2. Approve modifications to Biologics PA criteria and add “biologic” DMARD to Q#13
3. Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd. All in favor. Approved.

D. Substance Use Disorders Class Update (pages 118 – 143)

Dr. Gibler presented the scan and the following recommendations:

1. Approve modifications to buprenorphine & buprenorphine/naloxone products and injectable naltrexone PA criteria. Amend Vivitrol PA length to 6 months and add same PDMP language.
2. Remove buprenorphine sublingual tablets from PMPDP and restrict use to pregnant women and females actively trying to conceive
3. Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd. All in favor. Approved.

E. Class Literature Scans (pages 144 – 155)

Dr. Moretz and Dr. Gibler presented the following scans and recommendations:

1. Growth Hormones Scan
 - a. No further research is needed at this time
 - b. Maintain current PA criteria
 - c. Evaluate comparative costs in executive session
2. Parental Antipsychotics Scan
 - a. No further research is needed at this time
 - b. Maintain current PA criteria
 - c. Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd. All in favor. Approved.

F. Hepatitis C Class Update (pages 156 – 202)

Dr. Herink presented the new drug evaluations and class update along with the following recommendations:

- a. Approve recommended fibrosis blood testing-**All in favor**
- b. Amend expected survival from non-HCV-associated morbidities from 5 years to 1 year-**Majority not in favor**
- c. Allow treatment to F2-**deferred to a future meeting for more discussion**
- d. Allow specialist for F2-**deferred to a future meeting for more discussion**
- e. Training around F2-**deferred to a future meeting for more discussion**
- f. Approve changes to alcohol and SUD criteria-**Majority in favor**
- g. Include NS5A polymorphism testing-**All in favor**

ACTION: Motion to approve, 2nd. All in favor. Approved.

V. EXECUTIVE SESSION

VI. RECONVENE FOR PUBLIC RECOMMENDATIONS * After executive session

- A. Newer Diabetes Agents Drug Class Update (pages 34 – 47)
***ACTION:** Recommend no changes to the PMPDP
Motion, 2nd, All in Favor. Approved.
- B. Asthma/COPD Drug Class Update (pages 48 - 82)
***ACTION:** Make Ipratropium/Albuterol (Combivent Respimat) non-preferred and grandfather current users for 6 months; Make Ventolin HFA preferred on the PMPDP.
Motion, 2nd, All in Favor. Approved.
- C. Biologics Drug Class Update (pages 83 – 117)
***ACTION:** Make Canakinumab-pf non-preferred on the PMPDP.
Motion, 2nd, All in Favor. Approved.
- D. Substance Use Disorders Class Update (pages 118 – 143)
***ACTION:** Recommend no changes to the PMPDP.
Motion, 2nd, All in Favor. Approved.
- E. Growth Hormone Scan (pages 144 – 149)
***ACTION:** Make Saizen non-preferred and Genotropin preferred on the PMPDP.
Motion, 2nd, All in Favor. Approved.
- F. Parenteral Antipsychotics Scan (pages 150-155)
***ACTION:** Make Abilify Maintena and Aristada preferred on the PMPDP contingent upon executed supplemental rebate contracting.
Motion, 2nd, All in Favor. Approved
- G. Hepatitis C Class Update (pages 156 – 202)
***ACTION:** Make Zepatier the preferred regimen for GT1 and GT4, except decompensated; and make Epclusa preferred for GT2 and GT3 on the PMPDP.
Motion, 2nd, All in Favor. Approved

VII. ADJOURN